Current Report Filing (8-k)
September 16 2020 - 10:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 16, 2020
ANIXA
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37492
|
|
11-2622630
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
3150
Almaden Expressway, Suite 250
San
Jose, CA
|
|
95118
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (408) 708-9808
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.01 per share
|
|
ANIX
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01 Regulation FD Disclosure.
On
September 16, 2020, Anixa Biosciences, Inc. (the “Company”) presented at the 2020 H.C. Wainwright 22nd Annual Global
Investment Conference. Attached as Exhibit 99.1 to this Current Report is the form of presentation of the Company which was used
by management at the conference. This presentation may be used by the Company in the future at meetings with investors, analysts
or others, in whole or in part and possibly with modifications from time to time.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
The
following exhibits are filed with this Current Report on Form 8-K:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
September 16, 2020
|
ANIXA
BIOSCIENCES, INC.
|
|
|
|
|
By:
|
/s/
Amit Kumar
|
|
Name:
|
Dr.
Amit Kumar
|
|
Title:
|
President
and Chief Executive Officer
|
Anixa Biosciences (NASDAQ:ANIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anixa Biosciences (NASDAQ:ANIX)
Historical Stock Chart
From Apr 2023 to Apr 2024